The 16 references in paper E. Anaev Kh., Э. Анаев Х. (2017) “Современные представления об идиопатическом легочном фиброзе: в фокусе – биомаркеры // Current concepts of idiopathic pulmonary fibrosis: focus on biomarkers” / spz:neicon:pulmonology:y:2017:i:1:p:56-64

1
Hutchinson J., Fogarty A., Hubbard R., McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur. Respir. J. 2015; 46 (3): 795–806. DOI: 10.1183/09031936.00185114.
(check this in PDF content)
2
King T.E., Bradford W.Z., Castro-Bernardini S. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulПульмонология. 2017; 27 (1): 56–64. DOI: 10.18093/0869301893201732731356364 monary fibrosis. N. Engl. J. Med.2014; 370 (22): 2083–2092. DOI: 10.1056/NEJMoa1402582.
(check this in PDF content)
3
Richeldi L., du Bois R.M., Raghu G. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med.2014; 370 (22): 2071–2082. DOI: 10.1056/ NEJMoa1402584.
(check this in PDF content)
4
Woodcock H.V., Maher T.M. The treatment of idiopathic pulmonary fibrosis. F1000Prime Rep.2014; 6: 16. DOI: 10.12703/P6-16.
(check this in PDF content)
5
Pathak R.R., DavéV. Integrating omics technologies to study pulmonary physiology and pathology at the systems level. Cell Physiol. Biochem. 2014; 33 (5): 1239–1260. DOI: 10.1159/000358693.
(check this in PDF content)
6
Raghu G., Collard H.R., Egan J.J. et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med.2011; 183 (6): 788–824. DOI: 10.1164/rccm.2009-040GL.
(check this in PDF content)
7
Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Диагностика и лечение идиопатического легочного фиброза. Федеральные клинические рекомендации. Пульмоно( логия. 2016; 26 (4): 399–419. DOI: 10.18093/0869-01892016-26-4-399-419. / Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Federal Guidelines. Pul'monologiya. 2016; 26 (4): 399–419 (in Russian). DOI: 10.18093/08690189-2016-26-4-399-419.
(check this in PDF content)
8
Hutchinson J.P., Fogarty A.W., McKeever T.M., Hubbard R.B. In-hospital mortality after surgical lung biopsy for interstitial lung disease in the United States. 2000 to 2011. Am. J. Respir. Crit. Care Med. 2016; 193 (10): 1161–1167. DOI: 10.1164/rccm.201508-1632OC.
(check this in PDF content)
9
Ryerson C.J., Urbania T.H., Richeldi L. et al. Prevalence and prognosis of unclassifiable interstitial lung disease.Eur. Respir. J.2013; 42 (3): 750–757. DOI: 10.1183/09031936. 00131912. 17. Ley B., Bradford W.Z., Weycker D. et al. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. Eur. Respir. J. 2015; 45 (5): 1374–1381. 18. Kolb M., Collard H.R. Staging of idiopathic pulmonary fibrosis: past, present and future.Eur. Respir. Rev.2014; 23 (132): 220–224. DOI: 10.1183/09059180.00002114. 19. Ley B., Brown K.K., Collard H.R. Molecular biomarkers in idiopathic pulmonary fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 2014; 307 (9): L681–691. DOI: 10.1152/ajplung. 00014.2014. 20. Spagnolo P., Tzouvelekis A., Maher
(check this in PDF content)
10
1097/MCP.0000000000000187. 21. Han M.K., Zhou Y., Murray S. et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study.Lancet Respir. Med.2014; 2 (7): 548–556. DOI: 10.1016/S2213-2600(14)70069-4. 22. Jenkins R.G., Simpson J.K., Saini G. et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir. Med. 2015; 3 (6): 462–472. DOI: 10.1016/S2213-2600(15)00048-X. 23. Noth I., Zhang Y., Ma S.F. et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study.Lancet Respir. Med. 2013; 1 (4): 309–317. 24. Stock C.J., Sato H
(check this in PDF content)
11
King T.E., Pardo A., Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011; 378 (9807): 1949–1961. DOI: 10.1016/S0140-6736(11)60052-4.
(check this in PDF content)
12
Ahluwalia N., Shea B.S., Tager A.M. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. Am. J. Respir. Crit. Care Med.2014; 190 (8): 867–878. DOI: 10.1164/rccm.201403-0509PP.
(check this in PDF content)
13
Wolters P.J., Collard H.R., Jones K.D. Pathogenesis of idiopathic pulmonary fibrosis. Annu. Rev. Pathol.2014; 9: 157– 179. DOI: 10.1146/annurev-pathol-012513-104706.
(check this in PDF content)
14
Maher T.M. Beyond the diagnosis of idiopathic pulmonary fibrosis; the growing role of systems biology and stratified medicine. Curr. Opin. Pulm. Med. 2013; 19 (5): 460–465. DOI: 10.1097/MCP.0b013e328363f4b7.
(check this in PDF content)
15
du Bois R.M., Weycker D., Albera C. et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am. J. Respir. Crit. Care Med.2011; 184(12): 1382–1389.
(check this in PDF content)
16
du Bois R.M., Albera C., Bradford W.Z. et al. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 2014; 43 (5): 1421–1429. http:// journal.pulmonology.ru/pulm
(check this in PDF content)